Cargando…

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

BACKGROUND: Programmed cell death protein 1 (PD-1) is a key immune checkpoint that regulates peripheral tolerance and protects against autoimmunity. Programmed death ligand-2 (PD-L2) is a less studied ligand to PD-1 and has yet to be fully explored, especially in pancreatic ductal adenocarcinoma (PD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yiyin, Xu, Jin, Hua, Jie, Liu, Jiang, Liang, Chen, Meng, Qingcai, Wei, Miaoyan, Zhang, Bo, Yu, Xianjun, Shi, Si
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716876/ https://www.ncbi.nlm.nih.gov/pubmed/31464648 http://dx.doi.org/10.1186/s40425-019-0703-0

Ejemplares similares

The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction
por: Tan, Zhen, et al.
Publicado: (2020)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance
por: Meng, Qingcai, et al.
Publicado: (2020)

From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors
por: Wei, Miaoyan, et al.
Publicado: (2021)

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
por: Liu, Xiaomeng, et al.
Publicado: (2019)

Intra-tumoral infiltration of adipocyte facilitates the activation of antitumor immune response in pancreatic ductal adenocarcinoma
por: Liu, Xiaomeng, et al.
Publicado: (2022)

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2020)

Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)
por: Li, Jialin, et al.
Publicado: (2023)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Qian, Yunzhen, et al.
Publicado: (2022)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
por: Zhang, Yiyin, et al.
Publicado: (2018)

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
por: Chen, Ru, et al.
Publicado: (2014)

Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma
por: Katsuta, Eriko, et al.
Publicado: (2020)

Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer
por: Dong, Jia, et al.
Publicado: (2023)

Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma
por: Salmiheimo, Aino, et al.
Publicado: (2016)

Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma
por: Distler, Marius, et al.
Publicado: (2013)

Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma
por: Wilson, Gregory C., et al.
Publicado: (2023)

Cbl-b predicts postoperative survival in patients with resectable pancreatic ductal adenocarcinoma
por: Dong, Qian, et al.
Publicado: (2017)

A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma
por: Zhang, Li-xiang, et al.
Publicado: (2020)

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis
por: Rong, Zeyin, et al.
Publicado: (2021)

Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?
por: Gall, Tamara M.H., et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDAC
por: Dong, Mingwei, et al.
Publicado: (2023)

Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma
por: Sebastian, Nikhil T., et al.
Publicado: (2021)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma
por: Wu, Zijian, et al.
Publicado: (2022)

GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation
por: Meng, Qingcai, et al.
Publicado: (2018)

Tumor location as an indicator of survival in T1 resectable pancreatic ductal adenocarcinoma: a propensity score-matched analysis
por: Meng, Zibo, et al.
Publicado: (2019)

Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance
por: Zhang, Yiyin, et al.
Publicado: (2019)

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Yiyin, et al.
Publicado: (2019)

Impact of tumor size on survival of patients with resected pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
por: Li, Debang, et al.
Publicado: (2018)

Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma
por: Yoon, Kyoung Won, et al.
Publicado: (2011)

The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma
por: Ruess, Dietrich A., et al.
Publicado: (2015)

Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival
por: Morales-Oyarvide, Vicente, et al.
Publicado: (2017)

The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection
por: Murakawa, Masaaki, et al.
Publicado: (2019)

EGFR, but not COX-2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival
por: Fagman, Johan Bourghardt, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m65nv68s4v3cgfkmgn1nsgjp1p